Discovery of a dual CCR2/CCR5 antagonist with a superior cardiovascular profile for the treatment of autoimmune diseases

被引：0

作者：

Hughes, Robert O. ^{[1
]}

Rogier, D. Joseph ^{[1
]}

Devraj, Rajesh ^{[1
]}

Xue, Chu-Biao ^{[2
]}

Cao, Ganfeng ^{[2
]}

Turner, Steven R. ^{[1
]}

Morton, Philip A. ^{[1
]}

Keys, Kelly ^{[1
]}

Covington, Maryanne ^{[2
]}

Bond, Brian R. ^{[1
]}

Yu, Ying ^{[1
]}

Meade, Holly ^{[1
]}

Hood, William F. ^{[1
]}

Roeberds, Steve ^{[1
]}

Newton, Robert ^{[2
]}

Metcalf, Brian ^{[2
]}

机构：

[1] Pfizer Res & Dev, Cambridge, MA 02451 USA

[2] Incyte Corp, Willmington, DE 19880 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2011年 / 242卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

26-MEDI

引用

页数：1

共 50 条

[31] CCR2 and CCR5 expression on monocytes during in vivo culture
Dagkalis, N
Xu, H
Mack, M
Liversidge, J
Crane, IJ
IMMUNOLOGY, 2005, 116 : 75 - 75
[32] Dual CCR2/CCR5 Antagonist Cenicriviroc Leads to Potent and Significant Reduction in Proinflammatory CCR2+Monocyte Infiltration in Experimental Acute Liver Injury
Krenkel, Oliver
Puengel, Tobias
Mossanen, Jana C.
Ergen, Can
Heymann, Felix
Lefebvre, Eric
Trautwein, Christian
Tacke, Frank
HEPATOLOGY, 2015, 62 : 1065A - 1065A
[33] Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
Files, Daniel Clark
Tacke, Frank
O'Sullivan, Alexandra
Dorr, Patrick
Ferguson, William G.
Powderly, William G.
PLOS PATHOGENS, 2022, 18 (06)
[34] Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice
Mack, M
Cihak, J
Simonis, C
Luckow, B
Proudfoot, AEI
Plachy, J
Brühl, H
Frink, M
Anders, HJ
Vielhauer, V
Pfirstinger, J
Stangassinger, M
Schlöndorff, D
JOURNAL OF IMMUNOLOGY, 2001, 166 (07): : 4697 - 4704
[35] Anti-fibrotic and anti-inflammatory activity of the dual CCR5 and CCR2 antagonist cenicriviroc in a mouse model of NASH
Lefebvre, E.
Hashiguchi, T.
Jenkins, H.
Nabhan, A.
Yoneyama, H.
Friedman, S. L.
Wolfgang, G. H. I.
ANTIVIRAL THERAPY, 2013, 18 : A14 - A15
[36] WXSH0213, a dual CCR2 and CCR5 antagonist, ameliorates nonalcoholic activity score and liver fibrosis in MCD mice
Wang, Jianhua
Luo, Yunfu
Ba, Yuyong
Guo, Fengxun
Xu, Deming
Li, Jian
Chen, Shuhui
Chen, Xiaoxin
Liu, Xing
Li, Haijun
Liu, Zhuowei
Long, Chaofeng
HEPATOLOGY, 2017, 66 : 151A - 151A
[37] Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH
Lefebvre, Eric
Hashiguchi, Taishi
Jenkins, Helen
Nabhan, Antoun
Yoneyama, Hiroyuki
Friedman, Scott L.
Wolfgang, Grushenka H.
HEPATOLOGY, 2013, 58 : 221A - 222A
[38] Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
Bowler, S.
Siriwardhana, C.
Mitchell, B. L.
D'Antoni, M. L.
Ogata-Arakaki, D.
Souza, S.
Yee, R.
Gangcuangco, L. M. A.
Chow, D. C.
Ndhlovu, L. C.
Shikuma, C.
HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (4-5) : 123 - 129
[39] Dual Chemokine Receptor CCR2/CCR5 Antagonist Cenicriviroc Ameliorates Lipotoxicity-Induced Insulin Resistance and NASH in Mice
Ota, Tsuguhito
Chen, Guanliang
Nagashimada, Mayumi
DIABETES, 2019, 68
[40] THE DUAL CCR2/CCR5 ANTAGONIST CENICRIVIROC AMELIORATES STEATOHEPATITIS AND FIBROSIS IN VIVO BY INHIBITING THE INFILTRATION OF INFLAMMATORY MONOCYTES INTO INJURED LIVER
Puengel, T.
Krenkel, O.
Mossanen, J.
Longerich, T.
Lefebvre, E.
Trautwein, C.
Tacke, F.
JOURNAL OF HEPATOLOGY, 2016, 64 : S160 - S160

← 1 2 3 4 5 →